Reading time: 11 minutes

Thyroid disease detection in China has risen significantly with broader use of high-resolution ultrasound — thyroid nodules are detected in a substantial proportion of routine adult screenings, and thyroid cancer has become one of the more frequently diagnosed cancers among women in China [1]. The case volume has supported the maturation of Chinese centres in thyroid ultrasound, fine-needle aspiration (FNA), molecular markers (such as BRAF V600E), radiofrequency ablation (RFA) for thyroid nodules, and endoscopic thyroidectomy via transoral or breast-axillary approaches [2]. This article works through the disease categories — when drug therapy and surveillance are enough, when surgery or ablation are appropriate, which procedures are available, recommended Chinese centres, typical costs, and follow-up at home.

1. Treatment Pathways by Condition

Condition Primary management Typical cross-border indication?
Small asymptomatic benign nodule Periodic surveillance Not needed
Large or symptomatic benign nodule, or cosmetic concern Surgery or radiofrequency ablation (RFA) Appropriate
Hashimoto’s thyroiditis (hypothyroidism) Levothyroxine replacement Not needed
Graves’ disease (hyperthyroidism) Antithyroid drugs / radioiodine / surgery Complex cases yes
Cytologically indeterminate nodule (Bethesda III/IV) Molecular testing and re-evaluation, or diagnostic surgery Molecular testing can be useful
Papillary thyroid carcinoma (PTC, differentiated) Surgery ± radioiodine ± TSH suppression Appropriate
Medullary thyroid carcinoma (MTC) Surgery + genetic testing + systemic therapy Appropriate
Anaplastic thyroid carcinoma (ATC) Urgent multidisciplinary treatment Not appropriate for cross-border (urgent)

2. Radiofrequency Ablation (RFA) for Thyroid Nodules — A Mature Option in China

RFA and microwave ablation provide a way to treat benign nodules, selected recurrent micropapillary cancers, and metastatic cervical lymph nodes without an open neck incision. RFA has been widely adopted in China since the early 2010s, with substantial annual volumes at leading interventional ultrasound centres [2].

Indications for RFA:

  1. Benign nodule that is large or causing pressure or cosmetic concern, when the patient prefers to avoid surgery
  2. Repeated biopsies confirming benign histology
  3. Selected low-risk papillary microcarcinomas (PTMC, diameter under 1 cm, with specific criteria) — international guidelines remain cautious about cancer RFA and strict patient selection is essential [3]

Advantages of RFA:

  1. No neck scar
  2. Preservation of normal thyroid function
  3. Outpatient or short inpatient stay (1–3 days)
  4. Usually completed in a single session

Limitations of RFA:

  1. Does not completely remove the nodule — volume reduction of 50–80%
  2. Requires long-term surveillance — residual tissue may regrow
  3. Cannot replace central lymph node dissection — for cancer, standard surgery remains the first choice

Typical cost: USD 1,500–4,000 per session (depending on nodule size and device). US reference: USD 6,000–12,000 [4].

3. Endoscopic Thyroid Surgery (Scarless-Neck Approaches)

Several endoscopic approaches are now established at leading Chinese centres [5]:

  1. TOETVA (transoral endoscopic thyroidectomy vestibular approach): entry through the oral vestibule, no neck scar; appropriate for younger patients and those concerned about scarring
  2. Breast or chest-axillary approach: incision concealed at the breast or areola, avoiding the neck
  3. Axillary approach (ABBA): incision hidden in the axilla
  4. Robotic-assisted (da Vinci): available at some leading centres

Endoscopic vs traditional open: the cosmetic advantage is clear, but operative time is longer and the technique is more demanding. Cancer patients choosing endoscopic approaches should do so with experienced senior surgeons.

4. Thyroid Cancer Treatment

For differentiated thyroid cancer (PTC and FTC), 5-year survival in China is over 95%, consistent with Western data [6].

Typical treatment pathway:

  1. Ultrasound and FNA, with molecular testing where appropriate (BRAF V600E, RET, others)
  2. Surgery: lobectomy or total thyroidectomy, with central neck dissection ± lateral neck dissection
  3. Radioiodine therapy (for intermediate-to-high-risk patients)
  4. TSH suppression with levothyroxine
  5. Long-term surveillance (thyroglobulin and neck ultrasound)

Medullary and anaplastic carcinoma require systemic therapy. Available agents in China include:

  1. Vandetanib, cabozantinib, selpercatinib (RET inhibitors) — selected agents available
  2. Larotrectinib and entrectinib (NTRK inhibitors)
  3. Sorafenib and lenvatinib (multikinase inhibitors)

5. Hospitals to Consider

General thyroid surgery and endocrine head and neck surgery:

Hospital City
First Affiliated Hospital of China Medical University, Thyroid Surgery Shenyang
Peking Union Medical College Hospital, General Surgery Thyroid Group Beijing
Sun Yat-sen First Hospital, Thyroid Surgery Guangzhou
Fudan University Shanghai Cancer Center, Head and Neck Surgery Shanghai
Zhejiang Cancer Hospital, Thyroid Surgery Hangzhou
Tianjin Medical University Cancer Institute and Hospital, Head and Neck Surgery Tianjin
West China Hospital, Thyroid Surgery Chengdu
Sun Yat-sen Memorial Hospital, Thyroid Surgery Guangzhou

Leading centres for thyroid nodule RFA:

  1. PLA General Hospital (301), Department of Ultrasound Medicine
  2. Zhongshan Hospital, Fudan University, Department of Ultrasound
  3. Beijing Hospital, Interventional Department

6. Typical Process

Nodule evaluation plus RFA (4–7 days):

  1. Day 1: ultrasound and FNA
  2. Days 2–3: cytology results and molecular testing if needed
  3. Day 4: RFA (outpatient or short stay)
  4. Days 5–7: observation and discharge

Thyroid cancer surgery (7–10 days):

  1. Days 1–3: preoperative evaluation
  2. Day 4: surgery (open or endoscopic)
  3. Days 5–8: inpatient stay
  4. Days 9–10: discharge and suture removal

7. Typical Costs (USD, 1 USD = 6.5 RMB)

Item Public tertiary High-end private
Complete thyroid evaluation (ultrasound + FNA + molecular) 600–1,500 1,000–2,500
Benign nodule RFA 1,500–4,000 3,500–6,500
Unilateral lobectomy + central neck dissection (open) 4,000–7,000 7,000–12,000
Total thyroidectomy + bilateral central dissection 5,500–9,500 9,000–15,000
Endoscopic thyroid surgery (add-on) + 1,500–3,500
Lateral neck dissection (add-on) + 1,500–3,500
Radioiodine therapy 1,000–2,500 per session 1,500–3,500

8. Handing Care Back Home

  1. After thyroidectomy, lifelong levothyroxine replacement is required — available everywhere, with dose titration to TSH
  2. For thyroid cancer, lifelong follow-up with thyroglobulin and neck ultrasound is done at home
  3. Higher-risk patients are advised to maintain twice-yearly remote contact with the Chinese attending physician

9. What MedCareInChina Can and Cannot Do on the Thyroid Pathway

Our two products are Remote Consultation and In-China Accompanied Care.

  1. Remote Consultation: a USD 800 single-expert consultation with a thyroid specialist who reviews your ultrasound, pathology, and labs
  2. In-China Accompanied Care: hospital accompaniment with translation through evaluation, RFA or surgery, and post-operative review

What we do not do: long-term TSH suppression management, lifelong surveillance follow-up.

10. Action Checklist

  1. Bring neck ultrasound, FNA pathology, and a full thyroid function panel from the last 6 months
  2. Engage a remote consultation to confirm the plan (drug therapy / RFA / surgery)
  3. Apply for an S2 visa
  4. Plan 4–10 days in China
  5. After total thyroidectomy, take lifelong levothyroxine as prescribed
  6. Maintain contact with the Chinese attending physician for ongoing follow-up

Sources

[1] National Cancer Center of China — National incidence and mortality data for thyroid cancer [2] Chinese Medical Association Ultrasound Medicine Branch, Interventional Ultrasound Group — Chinese expert consensus on thermal ablation of thyroid nodules [3] American Thyroid Association — Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: https://www.thyroid.org/ [4] American Association of Endocrine Surgeons — Procedure cost references: https://www.endocrinesurgery.org/ [5] Anuwong A et al. — Transoral endoscopic thyroidectomy vestibular approach (TOETVA), peer-reviewed multi-centre outcome literature [6] SEER Cancer Statistics Review — Thyroid cancer: https://seer.cancer.gov/